GlassScriptPhysician profile
Mohammad Siddiqui
NPI 1003858275
$4,793.08
in general payments reported to CMS, 2019-2025
31 companies · $1,207 in 2025
The $1,207 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $141 · 2021: $659 · 2022: $497 · 2023: $698 · 2024: $1,071 · 2025: $1,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,888 · Education: $87.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,887.79 |
| Education | $87.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $708.25 | 2019-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $607.20 | 2019-2025 | Jynarque, Voyxact |
| Novartis Pharmaceuticals Corporation | $461.39 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $453.06 | 2019-2025 | Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $342.07 | 2021-2025 | Benlysta, Jesduvroq |
| Bayer Healthcare Pharmaceuticals INC. | $337.02 | 2021-2025 | |
| Amgen INC. | $235.00 | 2019-2025 | Tavneos, Aranesp, Parsabiv |
| Horizon Therapeutics Plc | $215.25 | 2020-2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $179.88 | 2021-2025 | Rayaldee |
| Akebia Therapeutics INC | $169.63 | 2021-2025 | Vafseo, Auryxia |
| Mallinckrodt Hospital Products INC. | $134.17 | 2020-2025 | Acthar, Terlivaz |
| Fresenius USA Marketing, INC. | $120.06 | 2022-2025 | Velphoro, Korsuva, Velphoro |
| Ani Pharmaceuticals, INC. | $110.29 | 2022-2024 | Purified Cortrophin Gel |
| Novo Nordisk INC | $91.06 | 2022-2025 | Ozempic |
| Travere Therapeutics, INC. | $84.52 | 2023-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $78.22 | 2021-2024 | Renal - Pd |
| Vantive US Healthcare LLC | $59.58 | 2025 | Renal - Pd |
| Lilly USA, LLC | $56.57 | 2024-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $52.91 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.91 | 2025 | Jardiance |
| Scpharmaceuticals INC. | $35.95 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $34.89 | 2025 | Voyxact |
| Apellis Pharmaceuticals, INC. | $23.30 | 2025 | Empaveli |
| Calliditas Therapeutics US INC. | $22.49 | 2024 | |
| Aurinia Pharma U.S., INC. | $22.35 | 2025 | Lupkynis |
| Kerecis Limited | $21.33 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Amicus Therapeutics, INC. | $20.15 | 2023 | Galafold |
| Ultragenyx Pharmaceutical INC. | $19.66 | 2020 | |
| Shire North American Group INC | $18.71 | 2019 | |
| Cycle Pharmaceuticals INC | $18.66 | 2025 | Venxxiva |
| Cormedix INC. | $13.55 | 2025 | Defencath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Siddiqui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.